
Edward M. Johnson
Examiner (ID: 7890, Phone: (571)272-1352 , Office: P/1736 )
| Most Active Art Unit | 1736 |
| Art Unit(s) | 1736, 1754, 1793 |
| Total Applications | 2442 |
| Issued Applications | 1938 |
| Pending Applications | 144 |
| Abandoned Applications | 375 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16778321
[patent_doc_number] => 20210115399
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => METHOD FOR DIFFERENTIATION INDUCTION IN CULTURED STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 17/063139
[patent_app_country] => US
[patent_app_date] => 2020-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063139
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/063139 | Method for differentiation induction in cultured stem cells | Oct 4, 2020 | Issued |
Array
(
[id] => 16870413
[patent_doc_number] => 20210163880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/039407
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039407
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039407 | BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES | Sep 29, 2020 | Abandoned |
Array
(
[id] => 19326170
[patent_doc_number] => 12043836
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => RNA-guided endonuclease expressing algal strain for high efficiency in vivo genome editing
[patent_app_type] => utility
[patent_app_number] => 17/039839
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 41
[patent_no_of_words] => 34709
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039839
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039839 | RNA-guided endonuclease expressing algal strain for high efficiency in vivo genome editing | Sep 29, 2020 | Issued |
Array
(
[id] => 16580680
[patent_doc_number] => 20210015082
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/039784
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 509
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039784
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039784 | ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF | Sep 29, 2020 | Abandoned |
Array
(
[id] => 17830405
[patent_doc_number] => 20220267709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => PHYSICAL MANIPULATION OF TISSUE CULTURED TISSUE
[patent_app_type] => utility
[patent_app_number] => 17/762316
[patent_app_country] => US
[patent_app_date] => 2020-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6495
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762316
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/762316 | Physical manipulation of tissue cultured tissue | Sep 21, 2020 | Issued |
Array
(
[id] => 16522893
[patent_doc_number] => 20200396973
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/014113
[patent_app_country] => US
[patent_app_date] => 2020-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17014113
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/014113 | PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF | Sep 7, 2020 | Abandoned |
Array
(
[id] => 17176814
[patent_doc_number] => 11154041
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-26
[patent_title] => Genetically modified non-human animal with human or chimeric genes
[patent_app_type] => utility
[patent_app_number] => 17/010054
[patent_app_country] => US
[patent_app_date] => 2020-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 55
[patent_no_of_words] => 30106
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010054
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/010054 | Genetically modified non-human animal with human or chimeric genes | Sep 1, 2020 | Issued |
Array
(
[id] => 16541339
[patent_doc_number] => 20200407752
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => MICROVESICLE AND METHOD FOR PRODUCING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/001319
[patent_app_country] => US
[patent_app_date] => 2020-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001319
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/001319 | MICROVESICLE AND METHOD FOR PRODUCING THE SAME | Aug 23, 2020 | Abandoned |
Array
(
[id] => 17867444
[patent_doc_number] => 20220290180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF ALPHA-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 17/635978
[patent_app_country] => US
[patent_app_date] => 2020-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23432
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -106
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17635978
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/635978 | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy | Aug 20, 2020 | Issued |
Array
(
[id] => 16484259
[patent_doc_number] => 20200377860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => THREE-DIMENSIONAL DIFFERENTIATION OF EPIBLAST SPHEROIDS TO KIDNEY ORGANOIDS MODELS STAGE-SPECIFIC EPITHELIAL PHYSIOLOGY, MORPHOGENESIS, AND DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/992362
[patent_app_country] => US
[patent_app_date] => 2020-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992362
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/992362 | THREE-DIMENSIONAL DIFFERENTIATION OF EPIBLAST SPHEROIDS TO KIDNEY ORGANOIDS MODELS STAGE-SPECIFIC EPITHELIAL PHYSIOLOGY, MORPHOGENESIS, AND DISEASE | Aug 12, 2020 | Pending |
Array
(
[id] => 16613942
[patent_doc_number] => 20210032595
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => METHOD FOR RECONSTRUCTING IMMUNE FUNCTION USING PLURIPOTENT STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 16/991758
[patent_app_country] => US
[patent_app_date] => 2020-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29334
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16991758
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/991758 | Method for reconstructing immune function using pluripotent stem cells | Aug 11, 2020 | Issued |
Array
(
[id] => 17609840
[patent_doc_number] => 20220152119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 17/290662
[patent_app_country] => US
[patent_app_date] => 2020-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4694
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290662
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290662 | COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS | Aug 9, 2020 | Pending |
Array
(
[id] => 17060293
[patent_doc_number] => 11104883
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-31
[patent_title] => SC-beta cells and compositions and methods for generating the same
[patent_app_type] => utility
[patent_app_number] => 16/934503
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 65
[patent_no_of_words] => 76304
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934503
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/934503 | SC-beta cells and compositions and methods for generating the same | Jul 20, 2020 | Issued |
Array
(
[id] => 17790607
[patent_doc_number] => 20220249698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => THERAPEUTIC AGENT FOR DISEASE CAUSED BY DOMINANT MUTANT GENE
[patent_app_type] => utility
[patent_app_number] => 17/626042
[patent_app_country] => US
[patent_app_date] => 2020-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 143
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17626042
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/626042 | THERAPEUTIC AGENT FOR DISEASE CAUSED BY DOMINANT MUTANT GENE | Jul 9, 2020 | Pending |
Array
(
[id] => 16391318
[patent_doc_number] => 20200332259
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => METHOD TO BIOENGINEER DESIGNER RED BLOOD CELLS USING GENE EDITING AND STEM CELL METHODOLOGIES
[patent_app_type] => utility
[patent_app_number] => 16/913741
[patent_app_country] => US
[patent_app_date] => 2020-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21019
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16913741
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/913741 | METHOD TO BIOENGINEER DESIGNER RED BLOOD CELLS USING GENE EDITING AND STEM CELL METHODOLOGIES | Jun 25, 2020 | Abandoned |
Array
(
[id] => 16837880
[patent_doc_number] => 20210145892
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
[patent_app_type] => utility
[patent_app_number] => 16/908037
[patent_app_country] => US
[patent_app_date] => 2020-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16908037
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/908037 | Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof | Jun 21, 2020 | Abandoned |
Array
(
[id] => 17958601
[patent_doc_number] => 20220339181
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => CONDITIONALLY SWITCHABLE NANOSTRUCTURE
[patent_app_type] => utility
[patent_app_number] => 17/620851
[patent_app_country] => US
[patent_app_date] => 2020-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 161
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620851
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/620851 | CONDITIONALLY SWITCHABLE NANOSTRUCTURE | Jun 21, 2020 | Pending |
Array
(
[id] => 17805958
[patent_doc_number] => 20220257793
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => COMPOSITIONS AND USE OF ENGINEERED MYOGENIC CELLS
[patent_app_type] => utility
[patent_app_number] => 17/614303
[patent_app_country] => US
[patent_app_date] => 2020-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36413
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614303
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/614303 | COMPOSITIONS AND USE OF ENGINEERED MYOGENIC CELLS | May 26, 2020 | Pending |
Array
(
[id] => 16674526
[patent_doc_number] => 20210063289
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => Functional Targeted Brain Endoskeletonization
[patent_app_type] => utility
[patent_app_number] => 16/860519
[patent_app_country] => US
[patent_app_date] => 2020-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7565
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860519
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/860519 | Functional Targeted Brain Endoskeletonization | Apr 27, 2020 | Abandoned |
Array
(
[id] => 16204883
[patent_doc_number] => 20200237873
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => SYSTEMS AND METHODS FOR ANGIOGENIC TREATMENT IN WOUND HEALING
[patent_app_type] => utility
[patent_app_number] => 16/846476
[patent_app_country] => US
[patent_app_date] => 2020-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11561
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846476
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/846476 | Systems and methods for angiogenic treatment in wound healing | Apr 12, 2020 | Issued |